Welcome to Telomium, a biotechnology company focused on immunotherapy
Telomium develops vaccines of a completely new class in the
pharmacopoeia: ribonucleoproteins, which have a unique ability to
orchestrate the break of immune tolerance against pathogenic tissues like cancer.
Our lead product TLVX01 is a first-in-class ribonucleoprotein based on telomerase. It has the ideal formulation to trigger
an autoimmune reaction targeted against almost any type of cancer... read more.